Marketwatch, July 13, 2021: Fees paid by drug companies make up half of the FDA’s revenue. Dr. Diana Zuckerman explains how these fees often influence FDA decisions and sacrifice patient safety.
Read More »Tag: drug safety
FDA Scrutinizes Pricey Cancer Drugs
Politico Pulse, April 28, 2021: Will FDA maintain approval for cancer drugs that are proven to not work? We were hoping for a reckoning, but that doesn’t seem likely as the doctors on the FDA Advisory panel tell FDA that they are hopeful that the drugs will eventually be proven to work.
Read More »NCHR Statement at FDA Advisory Committee Meeting on Tecentriq for Triple Negative Breast Cancer
April 27, 2021: A new randomized controlled trial that includes more Black women is needed to evaluate Tecentriq for Triple Negative Breast Cancer in order to keep FDA approval. The FDA doesn’t do patients any favors by continuing to approve a treatment that isn’t shown to help and may actually harm them.
Read More »